Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs STTK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Captures Overall Composite Edge (52.1 HOLD vs 44.8 HOLD), While CING Leads 3–1 on Growth & Valuation Pillars

STTK Overall Winner 6-Pillar Tally: CING 3 – 1 STTK (2 Tie) Matrix Metrics: CING 1 – 5 STTK

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cingulate Inc. (CING) on higher Unified Composite conviction (52.1/100 HOLD vs. 44.8/100 HOLD) after splitting the core matrix 5–1 (led by Profitability & Quality), while CING wins 3–1 across the 6-pillar growth and valuation breakdown. CING trades at $4.76 (N/M Forward P/E, 0.0% operating margin) versus STTK at $4.52 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. CING 44.8/100 HOLD) and 1.45β · 76% Vol risk profile, whereas CING leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs STTK
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.8 · SMA20: $4.71 · SMA50: $4.82
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.52
-3.0% 1D
Market Cap $473.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.45β · 76% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 35
RSI-14: 35.2 · SMA20: $5.18 · SMA50: $5.71

6-Pillar Scorecard Institutional Category Breakdown (CING 3 – 1 STTK)

Columns: Metric · CING · STTK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CING
Revenue Growth (YoY) +0.0% -66.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $62.5M $473.6M
3. Profitability & Quality STTK
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -198.7% -47.2%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$21M -$50M
Cash Flow Margin N/A N/A
Net Cash / Leverage $22M Net Cash $59M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.1% (16th %ile) 72.4% (10th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) 4.54x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (1) vs STTK (5)
Institutional Metric CING STTK Criterion Row Edge
Market Capitalization
Scale
$62.5M $473.6M Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -66.6% Higher Growth CING
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-198.7% -47.2% Higher ROE STTK
52-Week Range Position
Momentum
18% ($3–$12) 42% ($2–$8) Stronger Trend STTK
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 1.45β · 76% Vol Lower Realized Risk STTK
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$50M ($59M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CING +25.0 pp
CING: +9.17% · STTK: -15.83%
3M Horizon CING +31.31 pp
CING: -9.68% · STTK: -40.99%
6M Horizon CING +30.36 pp
CING: +8.43% · STTK: -21.93%
1Y Horizon STTK +104.04 pp
CING: +36.39% · STTK: +140.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs STTK. Trailing 12-month operating profitability (CING 0.0% vs STTK 0.0%) and valuation multiples (CING N/M vs STTK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
STTK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-47.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STTK BREAKDOWN
59d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.54x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $473.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs STTK Key Questions & Quantitative Answers

As of Nov 17, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cingulate Inc. (CING) on higher Unified Composite conviction (52.1/100 HOLD vs. 44.8/100 HOLD) after splitting the core matrix 5–1 (led by Profitability & Quality), while CING wins 3–1 across the 6-pillar growth and valuation breakdown. CING trades at $4.76 (N/M Forward P/E, 0.0% operating margin) versus STTK at $4.52 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. CING 44.8/100 HOLD) and 1.45β · 76% Vol risk profile, whereas CING leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CING leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with STTK at -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus N/A for STTK. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STTK.

CING and STTK trade at balanced relative valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus STTK (-47.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.45β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.